Increased bone marrow SUVmax on 18F-FDG PET is associated with higher pelvic treatment failure in patients with cervical cancer treated by chemoradiotherapy and brachytherapy

The aim of this study was to evaluate if bone marrow (BM) SUVmax measured on pre-treatment 18F-FDG PET/CT predicts the clinical outcome of locally advanced cervical cancer (LACC). We recruited retrospectively patients with LACC who underwent staging 18F-FDG PET/CT and had baseline blood tests, then...

Full description

Bibliographic Details
Main Authors: Romain-David Seban, Charlotte Robert, Laurent Dercle, Randy Yeh, Ariane Dunant, Sylvain Reuze, Antoine Schernberg, Roger Sun, Fabien Mignot, Marie Terroir, Martin Schlumberger, Christine Haie-Meder, Cyrus Chargari, Eric Deutsch
Format: Article
Language:English
Published: Taylor & Francis Group 2019-05-01
Series:OncoImmunology
Subjects:
Online Access:http://dx.doi.org/10.1080/2162402X.2019.1574197